Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Annovis Bio (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio Investor Brand Network - Mon Oct 7, 9:58AM CDT

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.33 (+1.59%)
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More Investor Brand Network - Fri Oct 4, 10:35AM CDT

NetworkNewsWire Editorial Coverage : Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address...

ANVS : 8.33 (+1.59%)
JNJ : 159.69 (+0.10%)
MRK : 108.52 (-0.06%)
NVS : 113.77 (-0.08%)
GSK : 38.02 (-1.58%)
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More FinancialNewsMedia - Thu Oct 3, 7:30AM CDT

EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END

ANVS : 8.33 (+1.59%)
JNJ : 159.69 (+0.10%)
MRK : 108.52 (-0.06%)
NVS : 113.77 (-0.08%)
GSK : 38.02 (-1.58%)
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases GlobeNewswire - Thu Oct 3, 7:30AM CDT

ANVS : 8.33 (+1.59%)
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition Investor Brand Network - Tue Oct 1, 9:28AM CDT

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug...

ANVS : 8.33 (+1.59%)
NVO : 117.20 (-0.48%)
LLY : 913.72 (+1.71%)
ABBV : 193.01 (-0.31%)
PFE : 29.18 (-0.07%)
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition FinancialNewsMedia - Tue Oct 1, 7:30AM CDT

EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END

ANVS : 8.33 (+1.59%)
NVO : 117.20 (-0.48%)
LLY : 913.72 (+1.71%)
ABBV : 193.01 (-0.31%)
PFE : 29.18 (-0.07%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market wealthyventurecapitalist.com - Fri Sep 27, 12:20AM CDT

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...

ANVS : 8.33 (+1.59%)
LLY : 913.72 (+1.71%)
INMB : 5.31 (+1.34%)
XBI : 97.10 (+0.80%)
BIIB : 182.30 (-0.57%)
SAVA : 26.05 (+2.52%)
Annovis Bio (NYSE: ANVS) Presented Recent Achievements at H.C. Wainwright Conference Investor Brand Network - Thu Sep 26, 9:15AM CDT

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

LGVN : 1.8400 (+1.10%)
ANVS : 8.33 (+1.59%)
AVXL : 5.24 (-2.42%)
Annovis Bio (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap Investor Brand Network - Mon Sep 23, 8:42AM CDT

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain...

ANVS : 8.33 (+1.59%)
Annovis Bio (NYSE: ANVS) to Participate at H.C. Wainwright Investment Conference Investor Brand Network - Fri Sep 6, 8:44AM CDT

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced...

ANVS : 8.33 (+1.59%)

Barchart Exclusives

S&P Futures Tick Lower Ahead of FOMC Meeting Minutes and More Fed Speak Barchart - 10 minutes ago
December S&P 500 E-Mini futures (ESZ24) are trending down -0.12% this morning as market participants awaited the Federal Reserve’s September meeting minutes and remarks from Fed officials. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot